Axsome Therapeutics has seen its stock price double in the past nine months, reaching a market capitalization of $12.6 billion. This significant growth is largely attributed to the recent FDA approval of its drug Auvelity for treating agitation associated with Alzheimer's disease. The company, which focuses on brain disorder treatments and historically self-funded its development, also has a robust pipeline with potential for annual new drug applications through 2030. AI
RANK_REASON Company stock performance driven by a new drug approval for a significant medical condition. [lever_c_demoted from significant: ic=1 ai=0.0]
- Alphabet
- Alzheimer's disease
- Axsome Therapeutics
- Bank of America Securities
- Eli Lilly
- Forbes
- Goldman Sachs
- Healthco/S.A.C. Capital
- Herriot Tabuteau
- Nvidia
- FDA
- William Blair
- Yale School of Medicine
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
